Crisdesalazine (AAD-2004) is an anti-inflammatory agent that simultaneously inhibits free radical- and prostaglandin E2 (PGE2)-mediated inflammation; it can be used in the study of neurodegeneration in amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.